May 19, 2008 -- Calando Pharmaceuticals of Pasadena, CA received a China patent for broad coverage of all methods of using any RNA interference construct formulated in a supramolecular complex. Supramolecular complex formulations are those formed with any type of polymer. The patent also covers any pharmaceutical compositions of matter containing RNAi constructs adapted for pulmonary or nasal delivery to the lungs. Calando Pharma is a majority owned subsidiary of Arrowhead Research Corp. (NSDQ: ARWR).
